(Q84567924)

English

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group

scientific article published on 15 July 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

AAML03P1, a pilot study of the safety of gemtuzumab ozogamicin in combination with chemotherapy for newly diagnosed childhood acute myeloid leukemia: a report from the Children's Oncology Group (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

acute myeloid leukemia

1 reference

based on heuristic

inferred from title

childhood acute myeloid leukemia

1 reference

based on heuristic

inferred from title

James H. Feusner

11

object named as

James Feusner

0 references

author name string

Todd M Cooper

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Janet Franklin

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Robert B Gerbing

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Todd A Alonzo

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Craig Hurwitz

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Susana C Raimondi

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Betsy Hirsch

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Franklin O Smith

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Prasad Mathew

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Robert J Arceci

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Robert Iannone

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Robert S Lavey

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Soheil Meshinchi

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Alan Gamis

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

publication date

15 July 2011

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

118

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

761-769

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results of children with acute myeloid leukemia: a report of three consecutive Phase III trials by the Children's Cancer Group: CCG 251, CCG 213 and CCG 2891.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment strategy and results in children treated on three Dutch Childhood Oncology Group acute myeloid leukemia trials.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment of childhood acute myeloblastic leukemia: dose intensification improves outcome and maintenance therapy is of no benefit--multicenter studies of the French LAME (Leucémie Aiguë Myéloblastique Enfant) Cooperative Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Treatment strategy and long-term results in paediatric patients treated in consecutive UK AML trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Pediatric Oncology Group (POG) studies of acute myeloid leukemia (AML): a review of four consecutive childhood AML trials conducted between 1981 and 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Successive clinical trials for childhood acute myeloid leukemia at St Jude Children's Research Hospital, from 1980 to 2000.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Long-term results in children with AML: NOPHO-AML Study Group--report of three consecutive trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Risk-stratified therapy and the intensive use of cytarabine improves the outcome in childhood acute myeloid leukemia: the AML99 trial from the Japanese Childhood AML Cooperative Study Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Calicheamicin-DNA complexes: warhead alignment and saccharide recognition of the minor groove

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin in pediatric CD33-positive acute lymphoblastic leukemia: first clinical experiences and relation with cellular sensitivity to single agent calicheamicin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

A feasibility study of simultaneous administration of gemtuzumab ozogamicin with intensive chemotherapy in induction and consolidation in younger patients with acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety and efficacy of gemtuzumab ozogamicin in combination with chemotherapy for pediatric acute myeloid leukemia: a report from the Children's Oncology Group

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Mitoxantrone and cytarabine induction, high-dose cytarabine, and etoposide intensification for pediatric patients with relapsed or refractory acute myeloid leukemia: Children's Cancer Group Study 2951.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Veno-occlusive disease of the liver after blood and marrow transplantation: analysis of pre- and post-transplant risk factors associated with severity and results of therapy with tissue plasminogen activator

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

The combination of randomized and historical controls in clinical trials

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.26190

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1002/CNCR.26190

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21766293%20AND%20SRC:MED&resulttype=core&format=json

7 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q84567924&oldid=1625598968"